Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
VANCOUVER, British Columbia, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or
“Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient from the U.S. for its multinational Phase 2b/3 human
study of NP-120 (Ifenprodil) for the treatment of COVID-19.
The Company is also pleased to announce that it has now enrolled 26 patients since the study began on August 5, 2020. The Phase 2b/3 study enrollment target is 150 patients, aggregated from all participating sites.
“We are very pleased to announce our first U.S. patient,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “We have also had steady enrollment from one of our International sites and as a result, we expect to reach 25% of our total target shortly.”
Phase 2b/3 Study Protocol Summary
The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."
The trial will begin as a Phase 2b study of an aggregate of 150 patients. With positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial.
Patients will be randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks.
Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation.
Phase 2b Study Completion and Data Readout
The Company will provide an update to the market shortly on a projected completion date as well as when the read out of the data can be expected.
About NP-120 (Ifenprodil)
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.